NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Societe Francaise de Rhumatologie
Conditions: Early Rheumatoid Arthritis or Early Undiffentiated Arthritis
The French Society of Rheumatology initiated a large national multicenter, longitudinal and prospective cohort, ESPOIR, in order to set up databases to allow various investigations on diagnosis, prognostic markers, epidemiology, pathogenesis and medico-economic factors in the field of early arthritis and rheumatoid arthritis. The primary objective is to set-up a multicentre cohort of early arthritis (less than 6 months) in France that could serve as a database to studies of various natures. Specific objectives are in the following domains: * diagnosis: to help determine among clinical, biological, radiographic and immunogenetics those parameters allowing for the earliest diagnosis classification as possible, in order to target early therapy; * prognosis: to identify early those patients at risk of severe disease by investigating among clinical, biological, genetic and sociologic factors; * medico-economic: to identify the costs and their determinants at various disease stage; * pathologic: to collect a databank of sera, DNA, RNA to allow for studies of transcriptomes and other genomics. Secondary objectives are twofold: * to monitor adverse events, particularly rare drug adverse events, in collaboration with other international studies * to allow access to the data collected in this cohort study in order to facilitate new projects submitted to and approved by the scientific committee.
Sex: ALL
Age: 18 Years to 70 Years
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria: * patients aged over 18 and under 70 * clinical diagnosis of rheumatoid arthritis as certain or probable * clinical diagnosis of undifferentiated arthritis potentially becoming rheumatoid arthritis * at least 2 inflammatory joints since 6 weeks : a swollen joint has to be observed in two articular sites and be present since at least 6 weeks * arthritis starting since less than 6 months * never prescribed DMARDS, corticoids, except if less than 2 weeks or except intra-articular injection less than 6 weeks before inclusion * corticosteroids could be tolerated if prescribed for duration less than 2 weeks in the month before the inclusion with an average dose less than 20 mg per day and stopped two weeks before inclusion Exclusion Criteria: * patients aged less than 18 years or aged more than 70 years * pregnant women * undifferentiated rheumatism with no potential chance to become rheumatoid arthritis * other inflammatory rheumatisms clearly defined